申请人:Eli Lilly and Company
公开号:US06498180B1
公开(公告)日:2002-12-24
Compounds of formula (I) in which R1 is halo-C1-10 alkyl; halo-C2-10 alkenyl; or (CH2)nY in which n is 1 or 2 and Y is OH, CN, N3, OR3, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO3H2; R3, R5, R6, R7, R8 and R9 are each selected independently from C1-4 alkyl, aryl and aryl-C1-4 alkyl; R4 is selected from C1-4 alkyl, aryl, aryl-C1-4 alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C1-4 alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R1 is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
式(I)中R1为卤代-C1-10烷基;卤代-C2-10烯基;或(CH2)nY,其中n为1或2,Y为OH,CN,N3,OR3,SH,S(O)pR4,S(O)3H,NH2,NHR5,NR6R7,NHCOR8,NO2,CO2H,CONHR9,1H-四唑-5-基,5-苯基四唑-2-基或PO3H2;R3,R5,R6,R7,R8和R9各自独立地选自C1-4烷基,芳基和芳基-C1-4烷基;R4选自C1-4烷基,芳基,芳基-C1-4烷基和1H-四唑-5-基,羧基-(1-4C)烷基和1H-四唑-5-基-C1-4烷基;p为0,1,2或3;或其盐或酯,前提是R1不是甲氧甲基,调节代谢型谷氨酸受体功能,并且在治疗中枢神经系统疾病中有用。